【レポートの概要（一部）】
1 Table of Contents
1 Table of Contents 10
1.1 List of Tables 17
1.2 List of Figures 23
2 Introduction 27
2.1 Related Reports 28
3 Disease Overview 29
3.1 Macular Degeneration Overview 29
3.1.1 Etiology and Pathophysiology 31
3.1.2 Classification 35
3.1.3 Symptoms and Diagnosis 37
3.2 Macular Edema Overview 40
3.2.1 Etiology and Pathophysiology 41
3.2.2 Classification 44
3.2.3 Symptoms and Diagnosis 45
4 Epidemiology – Macular Edema 48
4.1 Disease Background 48
4.2 Risk Factors and Comorbidities 48
4.3 Global Trends 49
4.3.1 US 50
4.3.2 5EU 50
4.3.3 Japan 51
4.4 Forecast Methodology 51
4.4.1 Sources Used 52
4.4.2 Sources Not Used 54
4.4.3 Forecast Assumptions and Methods — Diagnosed Prevalent Cases of Diabetes 55
4.4.4 Forecast Assumptions and Methods — Diagnosed Prevalent Cases of Diabetic Retinopathy 59
4.4.5 Forecast Assumptions and Methods – Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population 60
4.4.6 Forecast Assumptions and Methods – Total Prevalent Cases of ME following BRVO and CRVO 61
4.5 Epidemiological Forecast for Macular Edema (2013-2023) 62
4.5.1 Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population 62
4.5.2 Age-Specific Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population 64
4.5.3 Sex-Specific Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population 66
4.5.4 Total Prevalent Cases of ME Following BRVO 68
4.5.5 Age-Specific Total Prevalent Cases of ME Following BRVO 70
4.5.6 Sex-Specific Total Prevalent Cases of ME following BRVO 72
4.5.7 Total Prevalent Cases of ME Following CRVO 74
4.5.8 Age-Specific Total Prevalent Cases of ME Following CRVO 76
4.5.9 Sex-Specific Total Prevalent Cases of ME Following CRVO 78
4.6 Discussion 80
4.6.1 Epidemiological Forecast Insight 80
4.6.2 Limitations of the Analysis 81
4.6.3 Strengths of the Analysis 82
5 Epidemiology – Age-Related Macular Degeneration 83
5.1 Disease Background 83
5.2 Risk Factors and Comorbidities 84
5.3 Global Trends 85
5.3.1 US 85
5.3.2 5EU 86
5.3.3 Japan 86
5.4 Forecast Methodology 87
5.4.1 Sources Used 88
5.4.2 Forecast Assumptions and Methods 90
5.5 Epidemiological Forecast for AMD (2013-2023) 94
5.5.1 Total Prevalent Cases of AMD 94
5.5.2 Age-Specific Total Prevalent Cases of AMD 95
5.5.3 Sex-Specific Total Prevalent Cases of AMD 97
5.5.4 Age-Standardized Total Prevalence of AMD 99
5.5.5 Total Prevalent Cases of AMD by Stage 101
5.5.6 Total Prevalent Cases of Late AMD by Subtype 102
5.6 Discussion 104
5.6.1 Epidemiological Forecast Insight 104
5.6.2 Limitations of the Analysis 105
5.6.3 Strengths of the Analysis 106
6 Disease Management 107
6.1 Diagnosis and Treatment Overview 107
6.1.1 Macular Edema Diagnosis 107
6.1.2 Macular Degeneration Diagnosis 107
6.1.3 Treatment Guidelines and Leading Prescribed Drugs 108
6.1.4 Clinical Practice 110
6.2 US 123
6.3 France 127
6.4 Germany 130
6.5 Italy 133
6.6 Spain 136
6.7 UK 139
6.8 Japan 142
7 Competitive Assessment 145
7.1 Overview 145
7.2 Product Profiles – Major Brands 146
7.2.1 Lucentis (ranibizumab) 146
7.2.2 Eylea (aflibercept) 157
7.2.3 Avastin (bevacizumab) 168
7.2.4 Macugen (pegaptanib sodium) 175
7.2.5 Visudyne (verteporfin) 178
7.2.6 Corticosteroid Implants 183
8 Unmet Need and Opportunity 195
8.1 Overview 195
8.2 Treatment for Dry AMD 196
8.2.1 Unmet Need 196
8.2.2 Gap Analysis 198
8.2.3 Opportunity 200
8.3 Longer-Acting Anti-VEGF Drug Therapy 202
8.3.1 Unmet Need 202
8.3.2 Gap Analysis 204
8.3.3 Opportunity 204
8.4 Increased Efficacy of Anti-VEGF Therapy for wAMD 205
8.4.1 Unmet Need 205
8.4.2 Gap Analysis 206
8.4.3 Opportunity 207
8.5 Less Invasive Drug Formulations 207
8.5.1 Unmet Need 207
8.5.2 Gap Analysis 208
8.5.3 Opportunity 209
8.6 Awareness and Earlier Patient Diagnosis 210
8.6.1 Unmet Need 210
8.6.2 Gap Analysis 211
8.6.3 Opportunity 211
8.7 Home Monitoring of AMD Progression 212
8.7.1 Unmet Need 212
8.7.2 Gap Analysis 213
8.7.3 Opportunity 214
9 Pipeline Assessment 216
9.1 Overview 216
9.2 Clinical Trial Mapping 217
9.3 Promising Drugs in Clinical Development 218
9.3.1 Abicipar pegol 220
9.3.2 Fovista 227
9.3.3 Squalamine 235
9.3.4 Lampalizumab 243
9.3.5 Emixustat 250
9.3.6 Optina 257
9.3.7 DE-102 265
9.4 Promising Drugs in Early-Stage Development 269
9.4.1 Complement Inhibitors 269
9.5 Other Drugs in Development 271
9.6 Biosimilars 273
10 Current and Future Players 275
10.1 Overview 275
10.2 Trends in Corporate Strategy 277
10.3 Company Profiles 278
10.3.1 Roche/Genentech 278
10.3.2 Novartis 282
10.3.3 Regeneron 285
10.3.4 Bayer 289
10.3.5 Valeant 293
10.3.6 Allergan 296
10.3.7 Alimera Sciences 299
10.3.8 Ampio Pharmaceuticals 303
10.3.9 Ophthotech 305
10.3.10 Acucela 309
10.3.11 Ohr Pharmaceuticals 313
11 Market Outlook 316
11.1 Global Markets 316
11.1.1 Forecast 316
11.1.2 Drivers and Barriers – Global Issues 324
11.2 US 327
11.2.1 Forecast 327
11.2.2 Key Events 333
11.2.3 Drivers and Barriers 333
11.3 France 335
11.3.1 Forecast 335
11.3.2 Key Events 341
11.3.3 Drivers and Barriers 341
11.4 Germany 345
11.4.1 Forecast 345
11.4.2 Key Events 350
11.4.3 Drivers and Barriers 350
11.5 Italy 353
11.5.1 Forecast 353
11.5.2 Key Events 360
11.5.3 Drivers and Barriers 360
11.6 Spain 364
11.6.1 Forecast 364
11.6.2 Key Events 369
11.6.3 Drivers and Barriers 369
11.7 UK 372
11.7.1 Forecast 372
11.7.2 Key Events 378
11.7.3 Drivers and Barriers 378
11.8 Japan 382
11.8.1 Forecast 382
11.8.2 Key Events 388
11.8.3 Drivers and Barriers 388
12 Appendix 392
12.1 Bibliography 392
12.2 Abbreviations 427
12.3 Methodology 434
12.4 Forecasting Methodology 434
12.4.1 Diagnosed ME and AMD Patients 434
12.4.2 Percentage of Drug-Treated Patients 435
12.4.3 Drugs Included in Each Therapeutic Class 435
12.4.4 Launch and Patent Expiry Dates 435
12.4.5 General Pricing Assumptions 436
12.4.6 Individual Drug Assumptions 437
12.4.7 Pricing of Pipeline Agents 442
12.5 Primary Research – KOLs Interviewed for this Report 443
12.6 Primary Research – High-Prescribers Survey 444
12.7 About the Authors 445
12.7.1 Analyst 445
12.7.2 Therapy Area Director 445
12.7.3 Epidemiologist 446
12.7.4 Global Head of Healthcare 446
12.8 About GlobalData 447
12.9 Disclaimer 447
【レポート販売概要】
■ タイトル：黄斑浮腫・黄斑変性治療薬の世界市場予測および分析■ 英文：PharmaPoint: Macular Edema and Macular Degeneration - Global Drug Forecast and Market Analysis to 2023
■ 発行日：2014年10月31日
■ 調査会社：GlobalData
■ 商品コード：GDHC111PIDR
■ 調査対象地域：グローバル
- テレジオグラフィー・レポート及びデータベース（年間購読）The TeleGeography Report is our benchmark research service for the international long-distance industry. Our annual study of the international long-distance market has been published continuously since 1989, and is the most comprehensive source of data on the international long-distance market available anywhere.
- Endocarditis：グローバル臨床試験レビューH2, 2013Endocarditis Global Clinical Trials Review, H2, 2013 Summary GlobalData's clinical trial report, “Endocarditis Global Clinical Trials Review, H2, 2013" provides data on the Endocarditis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Endocarditis. It includes an overview of the trial numbers and their recruitment status as per the sit …
- 2014年戦略提言：アメリカの治療薬物モニタリング(TDM)市場This new 249-page report from Venture Planning Group provides a comprehensive analysis of the US therapeutic drug monitoring market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers. The report provides test volume and sales forecasts by country and market segment for the following assays: Amikacin, Carbamaze …
- 世界の機内エンターテインメント市場動向（2012-2016）TechNavio's analysts forecast the Global In-flight Entertainment market to grow at a CAGR of 6.65 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing number of aircraft orders. The Global In-flight Entertainment market has also been witnessing an increased number of new technologies and solutions. However, complying as per regulatory body …
- 目の病気用手術の世界市場：白内障手術、緑内障手術、糖尿病網膜症About Eye Care Surgical Devices Eye disorders such as cataract, glaucoma, diabetic retinopathy, diabetic macular edema, and other eye-related surgical disorders are mostly treated with eye care surgical instruments. Ophthalmic lasers are used to treat a variety of eye conditions such as tumors, glaucoma, age-related macular degeneration (AMD), diabetic retinopathy, retinal disorders, cataracts, an …
- 産業自動化制御の世界市場：DCS、PLC、ドライブ、センサAbout the Industrial Automation Control Market Industrial automation control solutions help organizations to optimize business operations through efficient control of various processes with minimal (or reduced) human intervention. The data collected from field devices and systems gives businesses a competitive edge. Automation solutions such as DCS, PLC, drives, and sensors improve organizational …
- 世界のレーザーホログラフィディスプレイ市場2015The Global Laser Holographic Display Industry 2015 Market Research Report is a professional and in-depth study on the current state of the Laser Holographic Display industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Laser Holographic Display market analysis is provided for the international markets in …
- 凍結治療の世界市場2019-2023About Cryotherapy Cryotherapy is a cold therapy and used for the treatment of pain by using freezing temperatures on a localized region of the body to eliminate an irritated nerve. Cryotherapy is also being increasingly adopted by dermatologists to treat abnormal skin cells. Technavio’s analysts forecast the Global Cryotherapy Market to grow at a CAGR of 8.45% during the period 2019-2023. Covered …
- 世界の紫外線硬化インク市場2015The Global UV Curable Inks Industry Report 2015 is a professional and in-depth study on the current state of the UV Curable Inks industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The UV Curable Inks market analysis is provided for the international markets including development trends, competitive landsc …
- 直鎖アルキルベンゼンスルホン酸塩（LAS）の世界市場About LAS LAS is also known as sodium dodecylbenzenesulfonate. These colorless salts, with organic formula C12H25C6H4SO3Na, are commercially manufactured in the form of mixtures of related sulfonates and find usage in the production of heavy-duty cleaners, laundry powders, light-duty dish-washing liquids, and industrial and household cleaners. Owing to their superior bio-degradability and environm …
- CRMにおけるビックデータ（Big Data in Customer Relationship Management (CRM)）Customer Relationship Management (CRM) is a model of managing relationship and interaction between company and customer. This includes using technology for organizing, automating, and synchronizing all customer-related information like sales, marketing, services, support and more. Big Data represents more than just a collection of data sets that form a large quantity of data, which is difficult to …
- Oil Search Limited：石油・ガスの開発・生産動向及びコスト分析- Q1, 2013Oil Search Limited Oil & Gas Exploration and Production Operations and Cost Analysis - Q1, 2013 Summary Oil Search Limited Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source for k …
- グローバル病院管理市場におけるトップ10企業分析Synopsis The ICD Research Global Top 10 Hospital Management Companies: Company Guide is a crucial resource for anyone looking to gain information on the top companies in the global healthcare industry. Detailed company profile and SWOT analysis information is provided for all the leading companies who are ranked in order by total annual revenues generated. Community Health Systems, Inc. Tenet Heal …
- 世界主要国のエルシニア検査（医療機器）市場The report presents a detailed analysis of the Yersinia diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Yersinia definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for the following market segments: - Hospitals - Commer …
- クラウドコミュニケーション：UCaaS市場One of the next waves in ICT is a migration of communications, applications, content, and commerce to the Cloud. Unified Communications in the Cloud (UCaaS) represents a powerful combination of core communications feature/functionality combined with many potential applications made available from a variety of companies. Multimedia communications is becoming increasingly important to business entit …
